Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers

Opinion
Video

Panelists discuss how the 5-year survival data for nivolumab plus chemotherapy underscore its sustained efficacy as a first-line treatment, showing durable benefits over alternatives. Further research, including real-world evidence and broader clinical trials, is needed to validate its long-term impact across diverse patient populations and cancer subtypes.

  • What insights do the 5-year survival data for nivolumab plus chemotherapy provide when considering its efficacy alongside other first-line treatments for these cancers?
  • ​What additional research or real-world evidence might be needed to further solidify the role of nivolumab plus chemotherapy based on these findings?
Recent Videos
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content